Published in Lancet on October 25, 2004
Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents (ORAR III) | NCT00552669
Rapamycin+Estradiol- vs. Rapamycin-Eluting Stents to Reduce Restenosis (ISAR-PEACE) | NCT00402636
Management of Antiplatelet Regimen During Surgical Procedures (MARS) | NCT03981835
PAclitaxel-eluting Balloon in Primary PCI in Amsterdam; Pilot Study (PAPPA-pilot) | NCT01274728
Drug eluting stents. BMJ (2006) 2.02
Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur Heart J (2009) 1.90
Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv (2011) 1.85
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J (2011) 1.71
Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol (2009) 1.55
Reducing In-Stent Restenosis: Therapeutic Manipulation of miRNA in Vascular Remodeling and Inflammation. J Am Coll Cardiol (2015) 1.52
Surgery is the best intervention for severe coronary artery disease. BMJ (2005) 1.25
Very late thrombosis after implantation of sirolimus eluting stent. Heart (2005) 1.23
Difference in neointimal coverage at chronic stage between bare metal stent and sirolimus-eluting stent evaluated at stent-strut level by optical coherence tomography. Heart Vessels (2013) 1.16
Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag (2008) 1.12
Is the difference in outcome between men and women treated by primary percutaneous coronary intervention age dependent? Gender difference in STEMI stratified on age. Eur Heart J Acute Cardiovasc Care (2013) 1.12
Drug-eluting stent thrombosis 1,659 days after stent deployment: case report and literature review. Tex Heart Inst J (2010) 1.09
Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol (2008) 1.07
Is late stent thrombosis in drug-eluting stents a real clinical issue? A single-center experience and review of the literature. Clin Res Cardiol (2006) 1.07
Application of a temporal reasoning framework tool in analysis of medical device adverse events. AMIA Annu Symp Proc (2011) 1.05
Coronary optical frequency domain imaging (OFDI) for in vivo evaluation of stent healing: comparison with light and electron microscopy. Eur Heart J (2010) 1.01
How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery. Clin Res Cardiol (2008) 0.99
Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-alpha expression in macrophages by reducing IL-10 expression. Mol Immunol (2009) 0.99
The Sirolimus-eluting coronary stent in daily routine practice in Germany: trends in indications over the years. Results from the prospective multi-centre German Cypher Stent Registry. Clin Res Cardiol (2007) 0.98
Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study. J Interv Cardiol (2014) 0.94
Estrogen receptor-mediated regulation of microRNA inhibits proliferation of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2012) 0.94
The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol (2009) 0.92
Continuous aspirin use does not increase post-endoscopic dissection bleeding risk for gastric neoplasms in patients on antiplatelet therapy. Endosc Int Open (2014) 0.91
Recent advances in drug eluting stents. Int J Pharm (2012) 0.91
Drug-eluting stents: some bare facts. Lancet (2004) 0.90
Bioresorbable scaffolds in the treatment of coronary artery disease. Med Devices (Auckl) (2013) 0.90
Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy. Heart (2007) 0.90
microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis. Adv Exp Med Biol (2015) 0.89
Endothelial progenitor cells: what use for the cardiologist? J Angiogenes Res (2010) 0.89
New drug-eluting stent concepts. Nat Rev Cardiol (2010) 0.89
Successful resection of complicated bleeding arteriovenous malformation of the jejunum in patients starting dual-antiplatelet therapy just after implanting a drug-eluting coronary stent. BMJ Case Rep (2012) 0.88
Drug-eluting stent: a review and update. Vasc Health Risk Manag (2005) 0.88
Prospective randomized trial comparing a nitinol self-expanding coronary stent with low-pressure dilatation and a high-pressure balloon expandable bare metal stent. Heart Vessels (2008) 0.87
Impact of an endothelial progenitor cell capturing stent on coronary microvascular function: comparison with drug-eluting stents. Korean J Intern Med (2014) 0.87
Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmgenomics Pers Med (2010) 0.87
Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries. Heart Vessels (2015) 0.87
Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience. Circ Cardiovasc Interv (2015) 0.86
One year clinical follow up of paclitaxel eluting stents for acute myocardial infarction compared with sirolimus eluting stents. Heart (2005) 0.86
A randomised controlled pilot trial to evaluate and optimize the use of anti-platelet agents in the perioperative management in patients undergoing general and abdominal surgery--the APAP trial (ISRCTN45810007). Langenbecks Arch Surg (2011) 0.86
Rapamycin inhibits re-endothelialization after percutaneous coronary intervention by impeding the proliferation and migration of endothelial cells and inducing apoptosis of endothelial progenitor cells. Tex Heart Inst J (2010) 0.85
Attenuated herpes simplex virus 1 blocks arterial apoptosis and intimal hyperplasia induced by balloon angioplasty and reduced blood flow. Proc Natl Acad Sci U S A (2007) 0.85
Vascular restoration therapy and bioresorbable vascular scaffold. Regen Biomater (2014) 0.84
Substrate-induced phenotypic switches of human smooth muscle cells: an in vitro study of in-stent restenosis activation pathways. J R Soc Interface (2010) 0.84
Advantages and disadvantages of biodegradable platforms in drug eluting stents. World J Cardiol (2011) 0.84
Very late stent thrombosis 42 months after implantation of sirolimus-eluting stent and discontinuation of antiplatelet therapy. Case Rep Med (2009) 0.84
Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy. Heart (2007) 0.84
Reduction of intimal hyperplasia in injured rat arteries promoted by catheter balloons coated with polyelectrolyte multilayers that contain plasmid DNA encoding PKCδ. Biomaterials (2012) 0.83
Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv (2015) 0.83
Diagnostic accuracy of in-stent coronary restenosis detection with multislice spiral computed tomography: a meta-analysis. Eur Radiol (2007) 0.83
Polyelectrolyte multilayers promote stent-mediated delivery of DNA to vascular tissue. Biomacromolecules (2013) 0.83
Delivery of large biopharmaceuticals from cardiovascular stents: a review. Biomacromolecules (2007) 0.83
Optimal revascularization for complex coronary artery disease. Nat Rev Cardiol (2013) 0.83
Endoscopic resection of bladder cancer in patients receiving double platelet antiaggregant therapy. Surg Endosc (2011) 0.83
Reporting of harm in randomized controlled trials evaluating stents for percutaneous coronary intervention. Trials (2009) 0.82
Intractable intraoperative bleeding requiring platelet transfusion during emergent cholecystectomy in a patient with dual antiplatelet therapy after drug-eluting coronary stent implantation (with video). BMJ Case Rep (2013) 0.82
Recent advances in primary percutaneous intervention for acute myocardial infarction. Heart (2005) 0.82
Clopidogrel and hip fractures, is it safe? A systematic review and meta-analysis. BMC Musculoskelet Disord (2016) 0.82
Outcomes of lung cancer surgery in patients with coronary artery disease: a decade of experience at a single institution. Surg Today (2016) 0.81
Nanoporous CREG-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. PLoS One (2013) 0.81
Comparison of long-term safety and efficacy outcomes after drug-eluting and bare-metal stent use across racial groups: Insights from NHLBI Dynamic Registry. Int J Cardiol (2015) 0.81
Long-term follow-up after coronary stenting with the sirolimus-eluting stent in clinical practice: results from the prospective multi-center German Cypher Stent Registry. Clin Res Cardiol (2012) 0.81
Association of localized hypersensitivity and in-stent neoatherosclerosis with the very late drug-eluting stent thrombosis. PLoS One (2014) 0.81
The dollars and sense of drug-eluting stents. CMAJ (2005) 0.81
Novel approach for endothelializing vascular devices: understanding and exploiting elastin-endothelial interactions. Ann Biomed Eng (2010) 0.81
Late angiographic stent thrombosis of polymer based paclitaxel eluting stent. Heart (2006) 0.80
Managing patients undergoing non-cardiac surgery: need to shift emphasis from risk stratification to risk modification. Heart (2006) 0.80
Liposomal simvastatin attenuates neointimal hyperplasia in rats. AAPS J (2010) 0.80
Incidence and clinical impact of stent fracture after the Nobori biolimus-eluting stent implantation. J Am Heart Assoc (2014) 0.80
Nitinol-based nanotubular coatings for the modulation of human vascular cell function. Nano Lett (2014) 0.79
A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease. Biologics (2013) 0.79
Antiplatelet therapy in patients undergoing coronary stenting: The risk of late stent thrombosis. Neth Heart J (2006) 0.79
A use case study on late stent thrombosis for ontology-based temporal reasoning and analysis. J Biomed Semantics (2014) 0.79
Treatment of in-stent restenosis with sirolimus-eluting-stents: results from the prospective German Cypher stent registry. Clin Res Cardiol (2008) 0.79
In vitro and in vivo degradation of poly(D, L-lactide-co-glycolide)/amorphous calcium phosphate copolymer coated on metal stents. J Biomed Mater Res A (2011) 0.79
In situ re-endothelialization via multifunctional nanoscaffolds. ACS Nano (2014) 0.78
Cell-type- and cell-cycle-specific anti-mitogenesis by cicaprost. Prostaglandins Other Lipid Mediat (2010) 0.78
Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy. Neth Heart J (2007) 0.78
Concomitant use of clopidogrel and statins and risk of major adverse cardiovascular events following coronary stent implantation. Br J Clin Pharmacol (2012) 0.78
Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents. Heart Vessels (2011) 0.78
Evaluation of prolonged safety and efficacy of biodegradable polymer coated sirolimus-eluting coronary stent system: 1-year outcomes of the INDOLIMUS Registry. Cardiovasc Diagn Ther (2015) 0.78
Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration. Pharmacol Res (2014) 0.78
Clinical utility of platinum chromium bare-metal stents in coronary heart disease. Med Devices (Auckl) (2015) 0.78
Perioperative management of antiplatelet therapy in patients with drug-eluting stents. HSR Proc Intensive Care Cardiovasc Anesth (2012) 0.78
Feasibility of aspirin continuation during the perioperative period for pulmonary resection in lung cancer patients: a retrospective study at a single institute in Japan. Surg Today (2014) 0.78
Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. PLoS One (2015) 0.77
Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. Vasc Health Risk Manag (2009) 0.77
Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model. Z Kardiol (2005) 0.77
Cardiovascular drugs: implications for dental practice. Part 2--antihyperlipidemics and antithrombotics. Anesth Prog (2008) 0.77
Thrombotic Thrombocytopenic Purpura associated with Clopidogrel: a case report and review of the literature. J Res Med Sci (2011) 0.77
Drug-eluting stents: current issues. Tex Heart Inst J (2005) 0.77
Simultaneous angiographic late stent thrombosis in two different coronary vessels after withdrawal of the combined anti-platelet therapy. Clin Res Cardiol (2006) 0.77
Cobalt-chrome MULTI-LINK VISION-stent implantation in diabetics and complex lesions: results from the DaVinci-Registry. Clin Res Cardiol (2009) 0.76
Investigating surface topology and cyclic-RGD peptide functionalization on vascular endothelialization. J Biomed Mater Res A (2013) 0.76
Sirolimus increases tissue factor expression but not activity in cultured human vascular smooth muscle cells. BMC Cardiovasc Disord (2005) 0.76
Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation. Neth Heart J (2011) 0.76
Shock wave lithotripsy in patients requiring anticoagulation or antiplatelet agents. Can Urol Assoc J (2011) 0.76
Delivery of paclitaxel from cobalt-chromium alloy surfaces without polymeric carriers. Biomaterials (2010) 0.76
Update on stents: recent studies on the TAXUS stent system in small vessels. Vasc Health Risk Manag (2007) 0.76
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr (2003) 11.88
A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35
Guidelines on myocardial revascularization. Eur Heart J (2010) 8.85
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55
Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA (2004) 8.12
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61
Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med (2010) 6.63
Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med (2015) 6.28
The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention (2005) 5.16
American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr (2004) 4.88
High-resolution spiral computed tomography coronary angiography in patients referred for diagnostic conventional coronary angiography. Circulation (2005) 4.68
Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol (2012) 4.29
Coronary-artery stents. N Engl J Med (2006) 4.13
Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest (2006) 4.06
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet (2009) 3.55
Guidelines on myocardial revascularization. Eur J Cardiothorac Surg (2010) 3.47
Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J (2011) 3.29
Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet (2007) 3.20
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med (2010) 3.17
Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16
A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (2008) 3.12
Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation (2006) 3.08
Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J (2009) 3.06
Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation (2003) 3.01
Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation (2010) 2.99
Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int J Cardiovasc Imaging (2002) 2.95
A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med (2007) 2.91
Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol (2005) 2.90
FIRST: Fractional Flow Reserve and Intravascular Ultrasound Relationship Study. J Am Coll Cardiol (2013) 2.87
Stent thrombosis. J Am Coll Cardiol (2010) 2.86
Comprehensive assessment of coronary artery stenoses: computed tomography coronary angiography versus conventional coronary angiography and correlation with fractional flow reserve in patients with stable angina. J Am Coll Cardiol (2008) 2.81
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol (2012) 2.78
Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation (2003) 2.72
Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. N Engl J Med (2011) 2.65
Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J Am Coll Cardiol (2003) 2.56
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol (2010) 2.55
Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet (2011) 2.54
Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation (2010) 2.54
Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts. N Engl J Med (2002) 2.52
Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol (2007) 2.50
Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol (2005) 2.50
Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. Eur Heart J (2012) 2.43
Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J (2005) 2.40
Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation (2009) 2.40
Feasibility of combined use of intravascular ultrasound radiofrequency data analysis and optical coherence tomography for detecting thin-cap fibroatheroma. Eur Heart J (2008) 2.36
The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol (2002) 2.34
Incidence and predictors of acute kidney injury after transcatheter aortic valve replacement. Am Heart J (2012) 2.33
Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. JACC Cardiovasc Interv (2013) 2.32
Intravascular ultrasound parameters associated with stent thrombosis after drug-eluting stent deployment. Am J Cardiol (2007) 2.32
Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation (2003) 2.31
Assessment of the aortic annulus by multislice computed tomography, contrast aortography, and trans-thoracic echocardiography in patients referred for transcatheter aortic valve implantation. Catheter Cardiovasc Interv (2011) 2.30
Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol (2010) 2.24
Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation (2011) 2.20
Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol (2003) 2.18